Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Status:
Completed
Trial end date:
2019-11-25
Target enrollment:
Participant gender:
Summary
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement
of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination